Article

Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
New England Journal of Medicine (Impact Factor: 54.42). 02/2000; 342(4):240-5. DOI: 10.1056/NEJM200001273420403
Source: PubMed

ABSTRACT Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the epsilon2 and the epsilon4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy.
We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans.
Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean follow-up period of 23.9+/-14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the epsilon2 or epsilon4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E epsilon3/epsilon3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon epsilon2/epsilon4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001).
The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention.

0 Followers
 · 
96 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral amyloid angiopathy (CAA) involves cerebrovascular amyloid deposition and is classified into several types according to the amyloid protein involved. Of these, sporadic amyloid β-protein (Aβ)-type CAA is most commonly found in older individuals and in patients with Alzheimer's disease (AD). Cerebrovascular Aβ deposits accompany functional and pathological changes in cerebral blood vessels (CAA-associated vasculopathies). CAA-associated vasculopathies lead to development of hemorrhagic lesions [lobar intracerebral macrohemorrhage, cortical microhemorrhage, and cortical superficial siderosis (cSS)/focal convexity subarachnoid hemorrhage (SAH)], ischemic lesions (cortical infarction and ischemic changes of the white matter), and encephalopathies that include subacute leukoencephalopathy caused by CAA-associated inflammation/angiitis. Thus, CAA is related to dementia, stroke, and encephalopathies. Recent advances in diagnostic procedures, particularly neuroimaging, have enabled us to establish a clinical diagnosis of CAA without brain biopsies. Sensitive magnetic resonance imaging (MRI) methods, such as gradient-echo T2* imaging and susceptibility-weighted imaging, are useful for detecting cortical microhemorrhages and cSS. Amyloid imaging with amyloid-binding positron emission tomography (PET) ligands, such as Pittsburgh Compound B, can detect CAA, although they cannot discriminate vascular from parenchymal amyloid deposits. In addition, cerebrospinal fluid markers may be useful, including levels of Aβ40 for CAA and anti-Aβ antibody for CAA-related inflammation. Moreover, cSS is closely associated with transient focal neurological episodes (TFNE). CAA-related inflammation/angiitis shares pathophysiology with amyloid-related imaging abnormalities (ARIA) induced by Aβ immunotherapies in AD patients. This article reviews CAA and CAA-related disorders with respect to their epidemiology, pathology, pathophysiology, clinical features, biomarkers, diagnosis, treatment, risk factors, and future perspectives.
    01/2015; 17(1):17. DOI:10.5853/jos.2015.17.1.17
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Restarting anticoagulants after an intracerebral hemorrhage (ICH) is one of the challenges that no physician feels happy to face: the available evidence is very weak to support any strong suggestion. Unfortunately, this is a rather frequent scenario given the large number of patients who are treated with anticoagulants, and the fact that intracerebral hemorrhage is not a rare complication of anticoagulants. Given the lack of any relevant randomized controlled trial, one needs to weigh the thromboembolic risk against the risk for re-bleeding to reach a clinical decision. Obviously, the long-term thromboembolic risk depends on the underlying condition with the most frequent causes being atrial fibrillation (AF), mechanical valves and venous thromboembolism (VTE). Moreover, one should keep in mind that a post-ICH patient is frequently bed-ridden, which further increases the risk for VTE regardless of and in addition to the underlying condition that initially required treatment with antico ...
    Internal and Emergency Medicine 11/2014; 10(1). DOI:10.1007/s11739-014-1160-x · 2.41 Impact Factor
  • Gerontology 01/2001; 47(3):119-130. DOI:10.1159/000052785 · 2.68 Impact Factor

Full-text (2 Sources)

Download
124 Downloads
Available from
May 20, 2014